We are monitoring the impact of COVID-19 on APAC Orphan Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1596
Share on
Share on

Asia Pacific Orphan Drugs Market Research Report – Segmented By Type, Therapeutic, Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, Forecast | 2020 to 2025

Pulished: February, 2020
ID: 1596
Pages: 145

The Asia Pacific Orphan Drugs Market size is projected to worth USD 32.14 billion in 2020 and estimated to be growing at a CAGR of 8.92%, to reach USD 49.28 billion by 2025.

As the Asian medicinal markets are still in a growing stage, the prospects for orphan drugs in Asia are also huge and getting increasingly prevalent. Compared with the U.S. and Europe, where there are about 400 orphan drugs obtainable, rare disease patients in this region have much less accessibility. However, some Asian countries have already instituted special regulatory methods for orphan drugs. Singapore established the Orphan Drug exemption to the Medicines Act in 1991 and Japan approved its Orphan Drug Regulation in 1993, permitting market exclusiveness for new orphan drugs for ten years.

MARKET DRIVERS

The introduction of reimbursement schemes and other new policies in favour of the ordinary people, rise in the number of rare diseases like inherited cancer diseases and neurodegenerative diseases are majorly driving the Asia Pacific orphan drugs market. The emergence of advanced technologies and the launch of innovative orphan drugs that have positive results in the treatment of rare diseases are the essential growth driving forces to the market. 

Furthermore, a growing number of patients suffering from various rare diseases related to cancer, cardiovascular problems and other rare diseases across the world are outshining the growth rate of the orphan drugs market in the Asia Pacific. These are manufactured specifically with a new formula to treat rare diseases, and hence the demand for this market is overgrowing.

Besides, government organizations focused on to improve the services in healthcare centres and to produce quality drugs in favour of the end-users, the rise in the concern towards health care among every individual and their prevalence for early diagnosis is elevating the growth rate of the APAC orphan drugs market.

MARKET RESTRAINTS

However, stringent rules and regulations by the government over pharmaceutical companies in concern towards the safety of the public, the manufacturing cost of orphan drugs is high compare to the standard drugs, and the lack of professionals in manufacturing drugs with the latest formula is the significant challenges to the market. 

This research report on the Asia Pacific orphan drugs market is segmented and sub-segmented into the following categories:

  • By Type: Biological and Non-biological
  • By Therapeutic: Haematology, Neurology, Oncology and Others
  • By Region: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

Regional Analysis

In the Asia Pacific, Chinese orphan drugs market has the fastest growth in this region due to rising approvals for orphan drugs from the Food and Drug Administration. China is the highest populated country in the world where the growing demand for orphan drug and actively promoting the regulation of rare diseases enhance the market. The number of key players has an interest in the development of an orphan drug to treat a rare disease. China is the hub of a rare disease, in this country majority of people suffered from infectious diseases. Also, the government has taken the initiatives for development in rare disease and expand the orphan drug market in domestic as well as global market. 

Indian orphan drugs market is also a fastest-growing country in APAC region due to rising geriatric patients and growing awareness of these drugs. Increasing various diseases such as cardiovascular disease, endocrinology, lymphatic system disorders, and respiratory disorders will also propel the demand for orphan drugs. There are substantial pharmaceutical industries focused on innovation and development of orphan drugs into the market.

Japanese orphan drugs market is expected to register a healthy CAGR in the coming years due to developed infrastructure and innovative technologies in healthcare industries. The government support and recent FDA approved for orphan drugs will grow the market across the region.

Leading companies operating in the APAC Orphan Drugs Market profiled in this report are Novartis, GlaxoSmithKline, Roche, Alexion, Sanofi, Bristol Myers Squibb, Pfizer, Vertex, Celgene, and Merck.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Type                              

                                5.1.1 Introduction           

                                5.1.2 Biological

                                5.1.3 Non Biological        

                                5.1.4  Y-o-Y Growth Analysis, By Type     

                                5.1.5  Market Attractiveness Analysis, By Type   

                                5.1.6  Market Share Analysis, By Type    

                5.2 Therapeutic                                

                                5.2.1 Haematology         

                                5.2.2 Neurology

                                5.2.3 Oncology 

                                5.2.4 Others      

                                5.2.5  Y-o-Y Growth Analysis, By Therapeutic       

                                5.2.6  Market Attractiveness Analysis, By Therapeutic     

                                5.2.7  Market Share Analysis, By Therapeutic      

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Type

                                                6.1.3.3 By Therapeutic

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Type

                                                6.1.4.3 By Therapeutic

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Type

                                                6.1.5.3 By Therapeutic

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Novartis                       

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 GlaxoSmithKline                      

                8.3 Roche                           

                8.4 Alexion                        

                8.5 Sanofi                           

                8.6 Bristol Myers Squibb                              

                8.7 Pfizer                            

                8.8 Vertex                          

                8.9 Celgene                       

                8.10 Merck                        

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Asia-Pacific Orphan Drugs Market By Type, From 2020 to 2025  ( USD Billion )
  2. Asia-Pacific Biological Market By Region, From 2020 to 2025  ( USD Billion )
  3. Asia-Pacific Non Biological Market By Region, From 2020 to 2025  ( USD Billion )
  4. Asia-Pacific Orphan Drugs Market By Therapeutic, From 2020 to 2025  ( USD Billion )
  5. Asia-Pacific Haematology Market By Region, From 2020 to 2025  ( USD Billion )
  6. Asia-Pacific Neurology Market By Region, From 2020 to 2025  ( USD Billion )
  7. Asia-Pacific Oncology Market By Region, From 2020 to 2025  ( USD Billion )
  8. Asia-Pacific Other therapeutics Market By Region, From 2020 to 2025  ( USD Billion )
  9. Japan Orphan Drugs Market By Type, From 2020 to 2025  ( USD Billion )
  10. Japan Orphan Drugs Market By Therapeutic, From 2020 to 2025  ( USD Billion )
  11. China Orphan Drugs Market By Type, From 2020 to 2025  ( USD Billion )
  12. China Orphan Drugs Market By Therapeutic, From 2020 to 2025  ( USD Billion )
  13. India Orphan Drugs Market By Type, From 2020 to 2025  ( USD Billion )
  14. India Orphan Drugs Market By Therapeutic, From 2020 to 2025  ( USD Billion )
  15. Australia Orphan Drugs Market By Type, From 2020 to 2025  ( USD Billion )
  16. Australia Orphan Drugs Market By Therapeutic, From 2020 to 2025  ( USD Billion )
  17. South Korea Orphan Drugs Market By Type, From 2020 to 2025  ( USD Billion )
  18. South Korea Orphan Drugs Market By Therapeutic, From 2020 to 2025  ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample